Search results for " oncologia"

showing 10 items of 366 documents

WhatsApp Messenger use in oncology: a narrative review on pros and contras of a flexible and practical, non-specific communication tool.

2021

The spread of instant messenger systems provides an excellent opportunity and a helpful tool to healthcare professionals. WhatsApp instant messenger use is widely prevalent among health professionals, cancer patients, caregivers and the general population. It is a quick and easy communication tool that may also be used on personal computers and business purposes. WhatsApp instant messenger and other similar tools may be a very useful complement for e-medicine. Instant messaging systems may be helpful, especially in rural areas, in medium- or low-income countries, or to avoid unnecessary travels, improve knowledge and awareness of cancer, monitor home care and support the delivery of home ca…

Social mediaOncologySettore MED/06 - Oncologia MedicaInstant messenger systemWhatsAppCancer careCancer researchSettore MED/42 - Igiene Generale E ApplicataHealth professional’s interactionTelemedicineEcancermedicalscience
researchProduct

BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.

2013

Abstract: Introduction: Several new targeted agents with anti-angiogenic properties have been developed recently, including vandetanib, sunitinib, sorafenib, bevacizumab and others. Tumor development, progression, metastasis are strongly linked to angiogenesis. Targeted agents like bevacizumab, a monoclonal antibody which targets VEGF, have been fully developed in several solid tumors. These new agents strongly advocate that targeting angiogenesis is one of the best approaches for cancer therapy. Areas covered: Those agents that target additional pro-angiogenic intracellular signaling pathways beyond VEGF signaling have also the potential to contribute to anticancer therapies. The authors p…

SorafenibIndolesLung NeoplasmsBevacizumabSettore MED/06 - Oncologia MedicaAngiogenesis InhibitorsPharmacologyVandetanibMetastasischemistry.chemical_compoundCarcinoma Non-Small-Cell LungmedicineAnimalsHumansPharmacology (medical)Lung cancerProtein Kinase InhibitorsPharmacologyNeovascularization Pathologicbusiness.industrySunitinibPharmacology. Therapyanti-angiogenesis BIBF 1120 nintedanib non-small cell lung cancer vascular endothelial growth factorGeneral MedicineProtein-Tyrosine Kinasesmedicine.diseaseVascular endothelial growth factorchemistryCancer researchNintedanibbusinessmedicine.drugExpert opinion on investigational drugs
researchProduct

The role of targeted therapy for gastrointestinal tumors

2014

Abstract: Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinic…

SorafenibOncologyVascular Endothelial Growth Factor Amedicine.medical_specialtyReceptor ErbB-2Hepatocellular carcinomaSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntineoplastic AgentsNeuroendocrine tumorsTargeted therapyTargeted therapychemistry.chemical_compoundNeuroendocrine tumorTrastuzumabInternal medicineRegorafenibmedicineHumansGastrointestinal tumorsMolecular Targeted TherapyProtein Kinase InhibitorsGastrointestinal NeoplasmsEverolimusHepatologySunitinibbusiness.industryColorectal cancer; Gastric cancer; Gastrointestinal tumors; Hepatocellular carcinoma; Neuroendocrine tumors; Targeted therapy; Hepatology; GastroenterologyGastrointestinal tumorGastroenterologyCancermedicine.diseaseColorectal cancerErbB ReceptorsReceptors Vascular Endothelial Growth FactorchemistryHuman medicineNeuroendocrine tumorsbusinessGastric cancermedicine.drug
researchProduct

Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy

2015

Abstract: Introduction: Angiogenesis is fundamental for tumor development and progression. Hence, anti-angiogenic drugs have been developed to target VEGF and its receptors (VEGFRs). Several tyrosine kinase inhibitors (TKIs) have been developed over the years and others are still under investigation, each anti-VEGFR TKI showing a different cardiotoxic profile. Knowledge of the cardiac side-effects of each drug and the magnitude of their expression and frequency can lead to a specific approach. Areas covered: This work reviews the mechanism of action of anti-VEGFR TKIs and the pathophysiological mechanisms leading to cardiotoxicity, followed by close examination of the most important drugs i…

SorafenibOncologymedicine.medical_specialtymedicine.drug_classSettore MED/06 - Oncologia MedicaAntineoplastic AgentsPharmacologyVandetanibModels BiologicalTyrosine-kinase inhibitorPazopanibchemistry.chemical_compoundInternal medicineRegorafenibNeoplasmsmedicineHumansPharmacology (medical)Molecular Targeted TherapyProtein Kinase Inhibitorstyrosine kinase inhibitor cardiac toxicityNeovascularization PathologicSunitinibbusiness.industryPharmacology. TherapyCancerHeartGeneral MedicineDrugs InvestigationalProtein-Tyrosine Kinasesmedicine.diseaseAxitinibReceptors Vascular Endothelial Growth FactorchemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Corrigendum to “Liquid biopsies in lung cancer: The new ambrosia of researchers” [Biochem. Biophys. Act. 1846(2014) 539–546]

2015

a Phase I — Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Wilrijkstraat 10, Edegem 2650, Belgium b Molecular Pathology Unit, Pathology Department, Antwerp University Hospital, Wilrijkstraat 10, Edegem 2650, Belgium c Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Via Liborio Giuffre 5, Palermo 90127, Italy d Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Holcombe Blvd 1400, Unit 455, Houston 77030, USA e Department of Biopathology and Medical and Forensic Biotechnologies, Section of Biology and Genetics, University of Palermo, V…

University campusCancer ResearchOncologyF-CenterSettore MED/06 - Oncologia MedicaGeneticsThe name of the author Daniele Santini was inadvertently omitted from the author line. The correct author line is above.Library scienceUniversity hospitalBiochimica et Biophysica Acta (BBA) - Reviews on Cancer
researchProduct

VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells

2014

Abstract Anti-VEGF therapy perturbs tumor metabolism, severely impairing oxygen, glucose, and ATP levels. In this study, we investigated the effects of anti-VEGF therapy in multiple experimental tumor models that differ in their glycolytic phenotypes to gain insights into optimal modulation of the metabolic features of this therapy. Prolonged treatments induced vascular regression and necrosis in tumor xenograft models, with highly glycolytic tumors becoming treatment resistant more rapidly than poorly glycolytic tumors. By PET imaging, prolonged treatments yielded an increase in both hypoxic and proliferative regions of tumors. A selection for highly glycolytic cells was noted and this met…

Vascular Endothelial Growth Factor ACancer ResearchPathologymedicine.medical_specialtyNecrosismedicine.medical_treatmentAngiogenesis InhibitorsMice SCIDBiologySCIDAntibodies Monoclonal HumanizedAntibodiesCell LineTargeted therapyMiceRandom AllocationCell Line TumorNeoplasmsMonoclonalAngiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Bevacizumab; Cell Line Tumor; Female; Glycolysis; Humans; MCF-7 Cells; Mice; Mice Inbred BALB C; Mice SCID; Molecular Targeted Therapy; Neoplasms; Phenotype; Random Allocation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor AssaysmedicineAnimalsHumansGlycolysisMolecular Targeted Therapycancer-cellAnti-VEGF therapyHumanizedInbred BALB CMED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAMice Inbred BALB CTumorpositron emission tomography antiangiogenesis glucose metabolism hypoxiaXenograft Model Antitumor AssaysPhenotypeBlockadeBevacizumabVascular endothelial growth factor APhenotypeOncologyCell cultureMonoclonalMCF-7 CellsCancer researchMED/06 - ONCOLOGIA MEDICAFemalemedicine.symptomGlycolysis
researchProduct

Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules

2011

The treatment of solid malignancies includes various target drugs, such as monoclonal antibodies and tyrosine kinase inhibitors, which exert their effect alone or in combination with chemotherapy. The main part of these molecules have a target on proteins of EGFR and VEGF pathways. The particular toxicity profile and the financial impact, deriving from the application of these agents in cancer treatment, prompted a lot of researches to define predictive factors of their efficacy. Various biomarker were identified among the components of the targeted pathways. However just few studies allowed to identify specific factors to predict the toxicity of these drugs. In this review EGFR and VEGF-re…

Vascular Endothelial Growth Factor Amedicine.drug_classSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryAngiogenesis InhibitorsAntineoplastic AgentsPharmacologyMonoclonal antibodyTargeted therapyAntineoplastic AgentNeoplasmsProtein-Tyrosine KinasemedicineHumansAngiogenesis Inhibitors; Antibodies Monoclonal; Antineoplastic Agents; Humans; Neoplasms; Protein-Tyrosine Kinases; Receptor Epidermal Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor ATarget therapyPharmacologyAnti vegfChemotherapybusiness.industryAntibodies MonoclonalProtein-Tyrosine KinasesErbB ReceptorsTreatment OutcomeToxicityCancer researchBiomarker (medicine)NeoplasmReceptor Epidermal Growth FactorbusinessTyrosine kinaseAngiogenesis InhibitorHuman
researchProduct

Oncogeriatry: Communication, sharing, coordination of an emerging reality. The IIIrd Official Meeting of the AIOM Working Group on Oncogeriatry

2010

The clinical management of the oncological elderly patient represents one of the most important challenges for today's oncology and, above all, for the future. The number of elderly patients with neoplastic pathologies is destined to increase proportionally to the duration of life and therefore a correct management of their conditions becomes an element of priority from the scientific and economic point of view. Close relationships and collaborations between Oncologist and Geriatrics are definitely desirable to be able to guarantee the best way for a good treatment (specific and of support) of these elderly patients. The components of the AIOM Working Group on Oncogeriatry have gathered the…

Working groupSettore MED/06 - Oncologia MedicaGuidelineOncogeriatry
researchProduct

Alteration of the YY1/RKIP ratio is a frequent event in hepatocellular carcinoma

2009

Yin Yang 1 Raf-1 kinase inhibitor protein Hepatocellular carcinoma ApoptosisSettore MED/12 - GastroenterologiaSettore MED/06 - Oncologia MedicaSettore BIO/14 - Farmacologia
researchProduct

“THERMAL NOCICEPTION STUDIES IN ZEBRAFISH”

2012

Background Nociception was defined by Sherrington as the mechanism used to sense painful events. Despite the value of current animal models for nociception and pain, we have not yet understood in full how these mechanisms operate. Aim Here we propose a novel approach using zebrafish (Danio rerio) larvae in order to determine if the fish is suitable for the study of pain stimuli. Taking advantage of the fact that, in response to noxious stimuli, the expression of several genes in mammals is induced in neurons of the spinal cord and the dorsal root ganglia (DRG), we investigated if such mechanism is evolutionary conserved in the Zebrafish. Materials and Methods We cloned homologues of mammals…

ZEBRAFISHSettore MED/06 - Oncologia MedicaNOCICEPTION
researchProduct